NEW YORK (GenomeWeb) – Leerink today initiated coverage of HTG Molecular with an Outperform rating for its stock and a target price of $6 per share.
In a note to investors, analyst Puneet Souda said that HTG has a growing funnel of biopharma partnerships and projects that have the potential to convert to US Food and Drug Administration-approved companion diagnostics and drive "significant revenue upside."